Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Episode Summary

Dr. Warrick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, shares highlights from the Fourth World Congress of Clinical Lipidology held in Vienna in June 2025. The episode explores cutting-edge research on cholesterol management, genetic factors in longevity, and emerging therapies that challenge conventional wisdom about heart disease prevention and treatment.

Key Takeaways:

• LDL cholesterol can only be utilized by the liver, not by other body tissues, which means there is no physiological threshold below which lowering LDL becomes harmful.

• Research from ancestral primates and hunter-gatherer tribes demonstrates that humans naturally maintain very low LDL cholesterol levels, much lower than modern Western populations.

• Lowering LDL cholesterol does not increase the risk of hemorrhagic stroke, and multiple major studies show that aggressive LDL reduction actually reduces all-cause mortality and dementia risk.

• Five-year cardiovascular risk assessments can be misleading; a 45-year-old with "low" short-term risk may face a 30-40% lifetime risk of heart attack, warranting early intervention based on lifetime risk rather than short-term projections.

• Obisetrapid, a new CETP inhibitor, uniquely both raises HDL and lowers LDL cholesterol, offering promise after previous drugs in this class caused harm.

• Famous "blue zones" associated with longevity in Italy (Campo di Melli and Le Bon Sul Garda) owe much of their protective effects to specific genetic mutations like ANGPTL3 that lower LDL and triglycerides, not just lifestyle factors.

• The APO A1 Milano genetic variant found in certain populations provides significant heart attack protection despite lower HDL levels, demonstrating that genetic factors sometimes override conventional risk markers.

• CRISPR gene-editing technology is approaching clinical reality and may revolutionize treatment of single-gene cholesterol disorders, with cardiology and lipidology potentially leading the world in implementing these therapies.

• Coronary artery disease should be viewed as a lifetime condition that begins building in young years, making early risk modification strategies far more effective than waiting for high short-term risk.